Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3

被引：0

作者：

Leypoldt, L. ^{[1
]}

Callander, N. S. ^{[2
]}

Richardson, P. G. ^{[3
]}

Hus, M. ^{[4
]}

Ribrag, V. ^{[5
]}

Lopez, J. M. ^{[6
]}

Kim, K. ^{[7
]}

Lee, J. H. ^{[8
]}

Dimopoulos, M. A. ^{[9
,10
]}

Schjesvold, F. ^{[11
,12
]}

Facon, T. ^{[13
]}

Jo, J. -C. ^{[14
]}

Min, C. -K. ^{[15
]}

Mielnik, M. ^{[4
]}

Cheng, S. ^{[16
]}

Smith, L. M. ^{[16
]}

Breitbach, C. J. ^{[16
]}

Brawley, C. ^{[17
]}

Sembhi, H. ^{[17
]}

LaMacchia, J. ^{[18
]}

Grosicki, S. ^{[19
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Katedra & Klin Hematoonkol & Transplantacji Szpik, Lublin, Poland

[5] Inst Gustave Roussy, Villejuif, France

[6] Univ Complutense Madrid, Hosp Univ 12 Octubre, Dept Hematol, CNIO,CIBERONC, Madrid, Spain

[7] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[8] Gachon Univ, Gachon Univ Gil Med Ctr, Coll Med, Incheon, South Korea

[9] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[10] Alexandra Hosp, Athens, Greece

[11] Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway

[12] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[13] Lille Univ Hosp, Dept Haematol, Lille, France

[14] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Ulsan, South Korea

[15] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[16] SpringWorks Therapeut, Stamford, CT USA

[17] GSK, Stevenage, Herts, England

[18] GSK, Waltham, MA USA

[19] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P330

引用

页码：176 / 177

页数：2

共 50 条

[31] Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
Ferron-Brady, Geraldine
Rathi, Chetan
Collins, Jon
Struemper, Herbert
Opalinska, Joanna
Jewell, Roxanne C.
BLOOD, 2020, 136
[32] Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3
Ferron-Brady, Geraldine
Taylor, Adekemi
Kaullen, Josh
Polireddy, Kishore
McKeown, Astrid
Sule, Neal
Struemper, Herbert
BLOOD, 2023, 142
[33] No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Lowther, Daniel E.
Houseman, E. Andres
Han, Gang
Kleanthous, Eleni
Knoblock, Dawson
Zhou, Xiangdong
Banerjee, Shreyan
Patel, Sagar
Figueroa, David
BLOOD, 2022, 140
[34] Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Weisel, Katja
Hopkins, Thomas G.
Fecteau, Doug
Bao, Weichao
Quigley, Corinne
Jewell, Roxanne C.
Nichols, Maureen
Opalinska, Joanna
BLOOD, 2019, 134
[35] DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
Callander, Natalie S.
Ribrag, Vincent
Richardson, Paul G.
Nooka, Ajay K.
Song, Kevin
Uttervall, Katarina
Minnema, Monique C.
Weisel, Katja
Quach, Hang
Min, Chang-Ki
Ballas, Marc S.
Li, Xiao fang
Ratia, Nirav
Kaisermann, Morrys
Holkova, Beata
Tudel, Suzanne
BLOOD, 2021, 138
[36] DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Trudel, S.
Nooka, A.
Fecteau, D.
Talekar, M.
Jewell, R. C.
Williams, D.
Evans, J.
Opalinska, J.
ANNALS OF ONCOLOGY, 2019, 30
[37] Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study
Lonial, S.
Vij, R.
Harousseau, J.
Facon, T.
Moreau, P.
Leleu, X.
Westland, C.
Singhal, A. K.
Jagannath, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[38] DREAMM-3: a phase III, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM)
Weisel, K.
Dimopoulos, M. A.
Hungria, V. T. M.
Radino, A.
Delimpasi, S.
Mikala, G.
Masszi, T.
Li, J.
Capra, M.
Matsumoto, M.
Sule, N.
Li, M.
McKeown, A.
He, W.
Bright, S.
Currie, B.
Boyle, J.
Opalinska, J.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 233 - 234
[39] Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
Trudel, Suzanne
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Quach, Hang
Vorobyev, Vladimir I.
Cavo, Michele
Suzuki, Kazuhito
Robak, Pawel
Morris, Kristin
Phillips-Jones, Amy
Zhou, Xiaoou Linnette
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Mateos, Maria-Victoria
Dimopoulos, Meletios Athanasios
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA105 - LBA105
[40] Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Dimopoulos, Meletios Athanasios
Hungria, Vania T. M.
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Maiolino, Angelo
Pappa, Vasiliki
Chraniuk, Dominik
Osipov, Iurii
Leleu, Xavier
Low, Michael
Matsumoto, Morio
Sule, Neal
Li, Mary
McKeown, Astrid
He, Wei
Bright, Shelley
Currie, Brooke
Perera, Sue
Boyle, Julia
Roy-Ghanta, Sumita
Opalinska, Joanna
Weisel, Katja
LANCET HAEMATOLOGY, 2023, 10 (10): : E801 - E812

← 1 2 3 4 5 →